← Product Code KGN · K090894 # COLLAWOUND WOUND DRESSING (K090894) _Collamatrix Co., Inc. · KGN · Jun 25, 2009 · SU · SESE_ **Canonical URL:** https://fda.innolitics.com/device/K090894 ## Device Facts - **Applicant:** Collamatrix Co., Inc. - **Product Code:** KGN - **Decision Date:** Jun 25, 2009 - **Decision:** SESE - **Submission Type:** Traditional - **Device Class:** Class U - **Review Panel:** SU - **Attributes:** Therapeutic ## Intended Use CollaWound wound dressing is intended for the management of wounds including: partial and full-thickness wounds; diabetic ulcers; venous ulcers; pressure ulcers; chronic vascular ulcers; tunneled/undermined wounds; surgical wounds (donor site/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence); trauma wounds (abrasions, lacerations, secondary-degree burns, and skin tears); draining wounds. ## Device Story CollaWound is a sterile, single-use, disposable wound dressing; composed of cross-linked porous collagen matrix; supplied in sponge configuration. Applied to wound site; forms thin film layer; provides biodegradable scaffold for cell invasion and capillary growth. Used in clinical settings for management of various acute and chronic wounds. Benefits patient by supporting tissue repair and wound healing. Device is applied by healthcare professionals. ## Clinical Evidence Bench testing only. Biocompatibility testing performed in accordance with ISO 10993 and FDA Blue Book memorandum G95-1. ## Technological Characteristics Cross-linked porous collagen matrix; sponge configuration; sterile; single-use; disposable. Biocompatibility compliant with ISO 10993. ## Predicate Devices - Colla Wound dressing ([K061474](/device/K061474.md)) - Bilayer Matrix Wound Dressing ([K021792](/device/K021792.md)) - AVAGEN Wound Dressing ([K022127](/device/K022127.md)) - Oasis SIS Wound Dressing ([K993948](/device/K993948.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ # Attachment 18 K090894 1/3 # COLLAMATRIX Co. Ltd. 510(k) summary Summary information ### 1. Date Prepared March 15, 2009 JUN 2 5 2009 ### Submitter name and address 2. Collamatrix Inc. 1st floor, No.50-1, Keyan Road, Jhunan Township Miaoli County, 350, Taiwan ### Contact person 3. | Name: | Dennis J. N. Seah | |-------|-------------------| | Tel: | + 886 2 7711 3299 | | Fax: | + 886 2 7711 5299 | #### 4. Device names | Propriety name: | CollaWound wound dressing | |----------------------|---------------------------| | Common name: | Wound dressing | | Classification name: | Collagen wound dressing | #### ડ. Device classification | Regulatory class: | Class II | |-------------------|----------| | Product code: | KGN | ### Device description 6. Page 1 of 3 {1}------------------------------------------------ KOGO894 2/3 # COLLAMATRIX Co. Ltd. CollaWound wound dressing is a sterile, single use, disposable wound dressing comprised of cross-linked porous collagen matrix with yellow to off-yellow appearance and is supplied in sponge configuration. It forms a layer of thin film at the wound site and provides a biodegradable scaffold for the cell invasion and capillary growth. #### 7. Intended use CollaWound wound dressing will be used for the management of partial- and fullthickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds, first and second degree burns, surgical wounds, draining wounds and trauma wounds. #### 8. Statement of Substantial equivalence CollaWound wound dressing is a collagen wound dressing device similar to predicate collagen-based devices that are previously approved by the agency and allowed for marketing towards the management of wounds. ## Predicate devices are listed below | Trade name: | Colla Wound dressing (K061474) | |-------------|-----------------------------------------| | Company: | Collamatrix Inc. | | Trade name: | Bilayer Matrix Wound Dressing (K021792) | | Company: | Integra Lifescience Corporation | | Trade name: | AVAGEN Wound Dressing (K022127) | | Company: | Integra Lifescience Corporation | | Trade name: | Oasis SIS Wound Dressing (K993948) | | Company: | COOK Biotech | The proposed device, CollaWound wound dressing, is another collagen wound dressing that is quite similar with respect to the indication for use, technological characteristics and material to the above devices in terms of the substantial equivalency under the 510(k) regulations. > 1st floor, No. 50-1, Keyan Road, Jhunan Township, Miaoli Country, 350, Taiwan Page 2 of 3 Tel: +886 2 7711 3299 Fax: +886 2 7711 5299 {2}------------------------------------------------ K090894 3/3 # COLLAMATRIX Co. Ltd. #### ਹੈ. Safety Biocompatibility tests have confirmed that CollaWound wound dressing meets the requirements stated in the FDA Blue book memorandum G95-1 and ISO 10993. ## 10. Conclusion CollaWound wound dressing is essentially equivalent in indication for use, technological characteristics and material to the commercially available predicate devices, and therefore meets the requirements as defined in 21 CFR § 807. Page 3 of 3 {3}------------------------------------------------ # DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES. USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle with its wings spread, symbolizing the department's mission to protect the health of all Americans and provide essential human services. ## Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 JUN 25 2009 Collamatrix Co., Inc. % Mr. Dennis J.N. Seah Manager 26F, No. 105, Section 2 DunHua South Road Daan district, Taipei 106 Taiwan Re: K090894 Trade/Device Name: CollaWound wound dressing Regulatory Class: Unclassified Product Code: FRO Dated: March 25, 2009 Received: March 31, 2009 Dear Mr. Seah: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA); it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical {4}------------------------------------------------ ## Page 2 - Mr. Dennis J.N. Seah device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/cdrh/mdr/ for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours. N. Melkerson Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ KO30854 ### 3 Statement of indications for use Device Name: To be determined Indications for Use: CollaWound wound dressing is intended for the management of wounds including: - partial and full-thickness wounds - - diabetic ulcers - venous ulcers - - pressure ulcers ー - chronic vascular ulcers - - tunneled/undermined wounds - - surgical wounds (donor site/grafts, post-Moh's surgery, post-laser surgery, . podiatric, wound dehiscence) - trauma wounds (abrasions, lacerations, secondary-degree burns, and skin tears) - draining wounds Prescription Use _____________________________________________________________________________________________________________________________________________________________ X AND/OR (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) 3-1 # (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Nal RPd (Division Sigh-Off) Division of Surgical, Orthopedic, and Restorative Devices 510(k) Number K090894 --- **Source:** [https://fda.innolitics.com/device/K090894](https://fda.innolitics.com/device/K090894) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com